Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics

Journal of Mathematical Biology

Volumn 64, Issue 3, 2012, Pages 557-577

  Ledzewicz, Urszula ^a   Naghnaeian, Mohammad ^b   Schättler, Heinz ^c  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; MOUSE; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84855706384     PISSN: 03036812     EISSN: 14321416     Source Type: Journal    
DOI: 10.1007/s00285-011-0424-6     Document Type: Article

References (34)

1. Bell DJ, Jacobson DH (1975) Singular optimal control problems. Academic Press, London.
2. Benson DA (2004) A Gauss pseudospectral transcription for optimal control, Ph. D. dissertation, Department of Aeronautics and Astronautics, MIT.
3. Benson DA, Huntington GT, Thorvaldsen TP, Rao AV (2006) Direct trajectory optimization and costate estimation via an orthogonal collocation method. J Guid Control Dyn 29(6): 1435-1440.
4. Bonnard B, Chyba M (2003) Singular trajectories and their role in control theory. In: Mathématiques & applications, vol 40. Springer, Paris.
5. Bressan A, Piccoli B (2007) Introduction to the mathematical theory of control. American Institute of Mathematical Sciences, Springfield.
6. Burden T, Ernstberger J, Fister KR (2004) Optimal control applied to immunotherapy. Discrete Contin Dyn Syst Ser B 4: 135-146.
7. Castiglione F, Piccoli B (2006) Optimal control in a model of dendritic cell transfection cancer immunotherapy. Bull Math Biol 68: 255-274.
8. de Pillis LG, Radunskaya A (2001) A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. J Theor Med 3: 79-100.
9. de Vladar HP, González JA (2004) Dynamic response of cancer under the influence of immunological activity and therapy. J Theor Biol 227: 335-348.
10. d'Onofrio A (2005) A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Phys D 208: 220-235.
11. d'Onofrio A (2006) Tumor-immune system interaction: modeling the tumor-stimulated proliferation of effectors and immunotherapy. Math Models Methods Appl Sci 16: 1375-1401.
12. d'Onofrio A, Gandolfi A, Rocca A (2009) The dynamics of tumour-vasculature interaction suggests low-dose, time-dense antiangiogenic schedulings. Cell Prolif 42: 317-329.
13. d'Onofrio A, Ledzewicz U, Maurer H, Schättler H (2009) On optimal delivery of combination therapy for tumors. Math Biosci 222: 13-26. doi: 10. 1016/j. mbs. 2009. 08. 004.
14. Ergun A, Camphausen K, Wein LM (2003) Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull Math Biol 65: 407-424.
15. Fister KR, Hughes Donnelly J (2005) Immunotherapy: an optimal control approach. Math Biosci Eng (MBE) 2(3): 499-510.
16. Golubitsky M, Guillemin V (1973) Stable mappings and their singularities. Springer, New York.
17. Guckenheimer J, Holmes P (1983) Nonlinear oscillations, dynamical systems, and bifurcations of vector fields. Springer, New York.
18. Huntington GT (May 2007) Advancement and analysis of a Gauss pseudospectral transcription for optimal control. Ph. D. dissertation, Department of Aeronautics and Astronautics, MIT.
19. Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J. Math Biol 37: 235-252.
20. Kuznetsov VA, Makalkin IA, Taylor MA, Perelson AS (1994) Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull Math Biol 56: 295-321.
21. Ledzewicz U, Marriott J, Maurer H, Schättler H (2010) Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. Math Med Biol 27: 157-179.
22. Ledzewicz U, Maurer H, Schättler H (2009) Bang-bang and singular controls in a mathematical model for combined anti-angiogenic and chemotherapy treatments. In: Proceedings of the 48th IEEE conference on decision and control, Shanghai, China, pp 2280-2285.
23. Ledzewicz U, Naghnaeian M, Schättler H (2010) Bifurcation of singular arcs in an optimal control problem for cancer immune system interactions under treatment. In: Proceedings of the 49th IEEE conference on decision and control. Atlanta, USA, pp 7039-7044.
24. Ledzewicz U, Naghnaeian M, Schättler H (2011a) An optimal control approach to cancer treatment under immunological activity. Appl Math 38(1): 17-31.
25. Ledzewicz U, Naghnaeian M, Schättler H (2011b) Dynamics of tumor-immune interactions under treatment as an optimal control problem. AIMS Proc (in press).
26. Ledzewicz U, Schättler H (2002) Analysis of a cell-cycle specific model for cancer chemotherapy. J Biol Syst 10: 183-206.
27. Ledzewicz U, Schättler H (2007) Anti-angiogenic therapy in cancer treatment as an optimal control problem. SIAM J Control Optim 46: 1052-1079.
28. Ledzewicz U, Schättler H (2008) Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. J Theor Biol 252: 295-312.
29. Norton L, Simon R (1977) Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 58: 1735-1741.
30. Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48: 7067-7071.
31. Rao AV, Benson DA, Huntington GT, Francolin C, Darby CL, Patterson MA (2008) User's Manual for GPOPS: a MATLAB package for dynamic optimization using the Gauss pseudospectral method, University of Florida report.
32. Stepanova NV (1980) Course of the immune reaction during the development of a malignant tumour. Biophysics 24: 917-923.
33. Swierniak A (2008) Direct and indirect control of cancer populations. Bull Pol Acad Sci Tech Sci 56(4): 367-378.
34. Swierniak A, Ledzewicz U, Schättler H (2003) Optimal control for a class of compartmental models in cancer chemotherapy. Int J Appl Math Comput Sci 13: 357-368.